Erschienen in:
09.08.2016 | Gastrointestinal Oncology
Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer
verfasst von:
Yutaka Yonemura, PhD, Haruaki Ishibashi, MD, Masamitu Hirano, PhD, Akiyoshi Mizumoto, PhD, Kazuyosi Takeshita, PhD, Kousuke Noguchi, PhD, Nobuyuki Takao, MD, Masumi Ichinose, PhD, Yang Liu, MD, Yan Li, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2017
Einloggen, um Zugang zu erhalten
Abstract
Background
The Peritoneal Cancer Index (PCI) is the most important prognostic factor following comprehensive treatment for peritoneal metastasis (PM) from gastric cancer (GCPM); however, 70 % of patients with GCPM showed a PCI score above the cut-off level at the time of diagnosis. Furthermore, neoadjuvant chemotherapy may reduce the PCI score to lower than the cut-off levels. In this study, the effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemoperfusion (NLHIPEC) and neoadjuvant intraperitoneal/systemic chemotherapy (NIPS) were investigated.
Materials and Methods
In group A, NLHIPEC was performed twice in 53 patients with GCPM, separated by a 1-month rest interval. Changes in the PCI were studied at the time of first and second laparoscopy. In group B, after NLHIPEC, a series of 3-week cycles of NIPS were performed over three courses in 52 patients. A laparotomy for cytoreductive surgery (CRS) was then carried out and the PCI changes were studied.
Results
In group A, the PCI score at the time of the second session (11.8 ± 11.0) was significantly lower than at the time of the first session (14.2 ± 10.7), while in group B, the PCI at the time of laparotomy (9.9 ± 11.3) was significantly lower than at the time of NLHIPEC (14.8 ± 11.4). After NLHIPEC plus NIPS, complete cytoreduction was achieved in 30 (57.6 %) patients.
Conclusions
NLHIPEC and NIPS are effective methods of reducing PCI levels before CRS.